CAJ | 학술논문

目的：研究鸦胆子油乳注射液联合卡培他滨治疗晚期结肠癌的临床疗效及毒副作用，为延长晚期结肠癌患者的生存时间提供指导。方法将36例晚期结肠癌患者随机分为治疗组和对照组，对照组患者采用卡培他滨（1250 mg/m2，bid，口服，共14 d）进行化疗，治疗组在对照组基础上再加用鸦胆子油乳注射液（30 mL静脉注射，qd，共7 d）进行联合治疗，3周为一个疗程，共8个疗程。对两组患者进行24个月的随访观察，比较两组的疗效及毒副作用和生存时间。结果治疗组的受益率显著高于对照组（P<0.05），但两组总有效率比较差异不显著（P>0.05）；对两组患者的治疗效果进行24个月随访观察，观察组的DFS（%）为16（66.67%），OFS（%）为11（45.83）均高于对照组的7（58.33%）、5（41.67%），但是差异不具有统计学意义（P>0.05）；中性粒细胞减少、血小板减少在两组间差异具有统计学意义（P<0.05），对照组的发生率明显高于治疗组。其他不良反应在两组间比较差异不具有统计学意义（P>0.05）；采用寿命表法计算两组中位生存期（治疗组为12个月、对照组9个月），两组比较差异不具有统计学意义（Z=2.688， P=0.101>0.05）。结论鸦胆子油联合卡培他滨治疗晚期结肠癌虽然对患者生存时间和疗效上差别不大，但是可以提高总体受益率，并且可以降低患者化疗的不良反应。
목적：연구아담자유유주사액연합잡배타빈치료만기결장암적림상료효급독부작용，위연장만기결장암환자적생존시간제공지도。방법장36례만기결장암환자수궤분위치료조화대조조，대조조환자채용잡배타빈（1250 mg/m2，bid，구복，공14 d）진행화료，치료조재대조조기출상재가용아담자유유주사액（30 mL정맥주사，qd，공7 d）진행연합치료，3주위일개료정，공8개료정。대량조환자진행24개월적수방관찰，비교량조적료효급독부작용화생존시간。결과치료조적수익솔현저고우대조조（P<0.05），단량조총유효솔비교차이불현저（P>0.05）；대량조환자적치료효과진행24개월수방관찰，관찰조적DFS（%）위16（66.67%），OFS（%）위11（45.83）균고우대조조적7（58.33%）、5（41.67%），단시차이불구유통계학의의（P>0.05）；중성립세포감소、혈소판감소재량조간차이구유통계학의의（P<0.05），대조조적발생솔명현고우치료조。기타불량반응재량조간비교차이불구유통계학의의（P>0.05）；채용수명표법계산량조중위생존기（치료조위12개월、대조조9개월），량조비교차이불구유통계학의의（Z=2.688， P=0.101>0.05）。결론아담자유연합잡배타빈치료만기결장암수연대환자생존시간화료효상차별불대，단시가이제고총체수익솔，병차가이강저환자화료적불량반응。
Objective To analyze the clinical curative effect and side effects of brucea javanica oil emulsion combined with capecitabine in treatment of advanced colorectal cancer. Methods Thirty six patients with advanced colorectal cancer were randomly divided into treatment group and control group, patients in control group were treated with capecitabine at a dose of 1 250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks), patients in treatment group were treated with capecitabine (same as in control group) combined with brucea javanica oil emulsion at a dose of 30 mL intravenously once daily for 1 week followed by a 2-week rest period, given as 3-week cycles for a total of 8 cycles (24 weeks). When treatment finished, the patients in two groups were followed up for 24 months to compare curative effects, side effects and survival time. Results Clinical benefit rate of patients in treatment group was significantly higher than that in control group (P<0.05), but there was no significant dif-ference based on the total efficiency between two groups (P>0.05). At the end of 24-month follow-up, DFS and OFS in control group were 16 (66.67%) and 11(45.83), while they were 7 (58.33), 5(41.67%) in treatment group (Z=-1.562, P=0.144>0.05). The benefit rate of patients in treatment group was 87.5%which was significantly higher than 58.33%in control group (X2=3.938, P=0.047). Significantly higher rate of neutrope-nia and thrombocytopenia was found in control group (P<0.05). The median survival period was 12 months in treatment group which was not significantly longer than 9 months in control group (Z=2.688, P=0.101>0.05). Conclusion Brucea javanica oil emulsion combined with capecitabine in treatment of advanced colorec-tal cancer is not superior to capecitabine alone, althought brucea javanica oil emulsion might improve the over-all benefit rate and reduce the adverse reaction of chemotherapy.